A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer
Latest Information Update: 10 Jan 2007
At a glance
- Drugs Lenalidomide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jan 2007 Status change
- 22 Oct 2005 New trial record.